- recruitingPHASE1, PHASE2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
This study is testing a new medicine, Tulmimetostat, for people with advanced cancers like solid tumours and lymphomas. It's looking at how safe it is, any side effects, and if it helps to shrink tumours.
United States · France · Italy - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - recruitingPHASE1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
This study is testing a new medicine called lunresertib, by itself or with other medicines (RP-3500 or Debio 0123), for people with advanced solid tumours. It aims to see if they are safe, what dose works best, and if they help shrink tumours.
United States · Canada · Denmark - recruitingPHASE1
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This study is testing a new medicine for people with advanced cancers that haven't responded to other treatments. It aims to see how safe the medicine is, how it moves through the body, and what dose works best.
United States · Canada - active not recruitingPHASE1
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
This study is looking at a new combination treatment, DS-1103a and T-DXd, for people with advanced solid tumours. It aims to see how safe and effective this new treatment is.
United States · Canada · France - recruitingPHASE1
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
This study tests an investigational drug called PhOx430 for advanced cancers that haven't responded to other treatments. It aims to find a safe dose and see how well it works, especially in certain types of solid tumours.
France · Italy - recruitingPHASE1, PHASE2
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study is testing a new treatment called BNT326, sometimes with other medicines, for people with advanced cancers. It aims to see if these treatments are safe, how well they work, and what dose is best.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
This study is testing a new drug, BT7480, alone and with an existing drug, nivolumab, for advanced cancers that have a specific marker called Nectin-4. We want to find the safest dose, understand side effects, and see how well it works.
United States · United Kingdom - active not recruitingPHASE1, PHASE2
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is testing a new drug, BT8009, alone or with another drug called pembrolizumab, for people with advanced cancers. It aims to find a safe and effective dose, understand how the body handles it, and see how well it works against different cancer types.
United States · Canada · France - recruitingPHASE1
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
This study is testing a new drug called IPH5301 for advanced cancers like breast, stomach, and lung. It's a first-time-in-human study, meaning it's the very first time this drug is being given to people. Researchers want to find a safe dose, either alone or with other treatments.
France - recruitingPHASE1
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
This study looks at a new drug, LY4050784, for advanced or metastatic solid cancers. We want to see if it's safe and effective, on its own or with other medicines, especially for cancers with a specific gene change called SMARCA4 (BRG1).
United States · France · Germany - recruitingPHASE1
ARC101 in Advanced Solid Tumors
This study is testing a new medicine, ARC101, for people with advanced cancer. It's the first time ARC101 is being given to humans, and doctors want to see if it's safe, how well the body handles it, and if it can help stop cancer from growing.
United States · Australia · Canada - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - recruitingPHASE1
Anti-GD2 ADC M3554 in Advanced Solid Tumors
This study is looking into a new medicine called M3554 for people with certain types of advanced cancer (soft tissue sarcoma or a brain tumour called glioblastoma). It aims to find the right dose, check if it's safe, and see how well it works against the cancer.
United States · Belgium · France - recruitingPHASE2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
This study is looking into a new medicine, Tovorafenib, for children and young adults aged 6 months to 25 years in the UK. It focuses on those with specific types of brain tumours (low-grade glioma) or advanced solid tumours that have come back or gotten worse, especially if they have certain genetic changes.
United States · Australia · Canada - recruitingPHASE1
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
This study is testing a new medicine, DO-2, for people with advanced solid tumours, especially lung cancer, that have specific genetic changes and where other treatments haven't worked. It aims to see if DO-2 is safe and how it moves through the body.
Belgium · France · Netherlands - recruitingPHASE1
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
This study looks at a new drug, CX-5461, for advanced solid tumours in patients with specific gene changes (like BRCA1/2). It aims to find the safest dose and see if the drug helps, also checking quality of life.
United States · Canada - recruitingPHASE1, PHASE2
A Study of YL201 in Patients With Advanced Solid Tumors
This study is testing a new medicine, YL201, for people with advanced cancers that haven't responded to other treatments. It will check if YL201 is safe and how well it works, sometimes given alongside another medicine called atezolizumab. It's an early-stage study happening in China and the US.
United States · Canada · China - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - not yet recruitingPHASE2
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
This study is testing a new treatment called MEDI5752 for advanced solid tumors. It's for people whose cancer has specific features and either haven't had immunotherapy before or it stopped working. The aim is to see how well MEDI5752 works.
France - recruitingPHASE1, PHASE2
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
This study is testing a new drug, IPN01203, for adults with advanced cancers that have spread. We're looking at its safety, best dose, and how well it works, especially for those who've had previous treatments. It's hoped to help control cancer growth.
United States · Canada · France - recruitingPHASE1, PHASE2
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
This study is testing a new drug, IMP1734, for people with advanced cancers. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumours. It's an early-stage study to gather information for future research.
United States · Australia · Canada - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - active not recruitingPHASE1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
This study is looking into a new medication called ALTA2618 for adults with certain advanced cancers that have a specific genetic change (AKT1 E17K mutation). The main goal is to check its safety and find the right dose.
United States · Australia · France - recruitingPHASE2
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
This study looks at new ways to treat advanced cancers by matching specific drugs to changes found in a patient's tumour genes. It tests three different drugs – atezolizumab, futibatinib, and amivantamab – to see how well they shrink tumours in different groups of patients.
France · Germany · Italy - active not recruitingPHASE1
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
This study is testing a new drug, NXP800, for people with advanced cancers. It aims to find a safe dose and see how well it works, especially for certain types of ovarian cancer that have a specific genetic change called ARID1a mutation.
United States · United Kingdom - active not recruitingPHASE1
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
This study is testing a new treatment called RP3, alone and with another drug called Nivolumab, for advanced cancers. It aims to find out if RP3 is safe and how much to give for future studies.
United States · France · Greece - recruitingPHASE1
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This study is testing a new drug, NXP900, for people with advanced cancers like lung cancer or kidney cancer. It's a very early-stage trial to see if the drug is safe and what dose works best.
United States · United Kingdom - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
This study is testing a new drug, BLU-222, for people with certain advanced cancers, including breast, ovarian, and stomach cancers. It aims to see how safe the drug is, how it moves through the body, and if it helps shrink tumors, both on its own and with other treatments.
France · Italy · Belgium - recruitingPHASE1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
This early-stage study is testing a new drug, MOMA-313, for advanced solid tumours, including prostate, breast, and pancreatic cancers. It aims to find a safe dose and see how it works, either alone or with another drug called Olaparib, in patients whose tumours have a specific genetic weakness.
United States · Spain · United Kingdom - recruitingPHASE1, PHASE2
First in Human Study of T3P-Y058-739 (T3P)
This study is testing a new treatment, T3P, for advanced solid tumours. It's a first human trial, looking at how safe and effective T3P is, both alone and with another drug called pembrolizumab, in adults aged 18-74.
Spain · Switzerland · United Kingdom - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors
This study is testing a new medicine called MK-1200 for people with advanced solid tumours. It aims to see how safe the drug is and if it helps shrink tumours. It's an early-stage study, combining two phases to learn about the drug's effects.
Spain · France · Italy - recruitingPHASE1
A Study of PYX-201 in Advanced Solid Tumors
This study is testing a new medicine, PYX-201, for people with advanced solid cancers. Doctors want to find the best dose and see if it shrinks tumours. It's an early-stage study to understand how safe and effective the medicine is.
United States · Belgium · Spain